Charles River Laboratories International, Inc. (CRL) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$272.88

Open

$272.78

Day range

$270.88 – $282.90

Volume

1.0M

About Charles River Laboratories International, Inc.

Latest CRL news

• Rat Model Market Outlook Signals Expansion To $2.8 Billion Through 2030
  Market Outlook · Aug 25, 2026

  The rat model market is projected to experience significant growth, reaching an estimated value of $2.8 billion by 2030. This expansion is driven by the increasing demand for advanced preclinical research models in drug development, as well as the rising prevalence of chronic diseases that necessitate extensive research and testing. The use of rat models is particularly favored due to their physiological and genetic similarities to humans, making them valuable for studying various human diseases and testing new therapies. Key factors contributing to this market growth include advancements in genetic engineering techniques, such as CRISPR, which allow for the creation of more precise and relevant animal models. Additionally, the growing emphasis on personalized medicine is pushing researchers to utilize rat models that can better mimic human responses to treatments. As pharmaceutical and biotechnology companies continue to invest in research and development, the demand for reliable and effective animal models is expected to rise, further propelling the market. Market implications suggest that companies involved in the production and supply of rat models may see increased opportunities for collaboration with research institutions and pharmaceutical firms. Moreover, as regulatory bodies emphasize the importance of preclinical testing, the rat model market may benefit from enhanced funding and support, solidifying its role in the broader landscape of biomedical research.

• Pharma Microbiology Testing Kits Market Outlook Signals Expansion To $11.97 Billion Through 2030
  Market Outlook · Aug 24, 2026

  The pharma microbiology testing kits market is poised for significant growth, with projections indicating an increase from $7.26 billion in 2025 to approximately $11.97 billion by 2030. This represents a robust compound annual growth rate (CAGR) of 10.8%, driven primarily by advancements in the biopharmaceutical pipeline and a rising preference for rapid testing technologies. The anticipated growth reflects the increasing demand for effective microbiological testing in drug development and quality control processes. Key factors contributing to this expansion include the ongoing evolution of the biopharmaceutical sector, which is seeing a surge in new drug candidates and therapies requiring rigorous microbiological testing. Additionally, the adoption of rapid testing methods is enhancing the efficiency and accuracy of microbial assessments, further propelling market growth. As regulatory standards continue to tighten, pharmaceutical companies are likely to invest more heavily in microbiology testing solutions, positioning themselves to meet compliance requirements while ensuring product safety. Market implications are significant, as this growth trajectory may attract increased investment in research and development within the microbiology testing sector. Companies that innovate and adapt to the changing landscape of pharmaceutical testing will likely gain a competitive edge, while those that fail to keep pace may struggle to maintain market share. Overall, the pharma microbiology testing kits market is set to play a crucial role in the broader pharmaceutical industry, supporting the development of safe and effective medical products.

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen